Tysabri and Cerebral Perivascular Spaces

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis
Post Reply
User avatar
HarryZ
Family Elder
Posts: 2572
Joined: Tue May 25, 2004 2:00 pm
Location: London, ON, Canada
Contact:

Tysabri and Cerebral Perivascular Spaces

Post by HarryZ »

I came across this abstract of a study they did involving Tysabri in use with MS patients. I'm reading that long term use of the drug reduces T lymphocytes in the immune system which is not good. Would appreciate any comments.

Harry



Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab.
Martin MD, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-Demasters BK, Stüve O.

Cravens, Frohman, Eagar, and Stüve and Mr Winger), Ophthalmology (Dr Frohman), Immunology (Drs Eagar, Karandikar, and Stüve), and Pathology (Dr Karandikar), University of Texas Southwestern Medical Center at Dallas; Departments of Neurology, The Ohio State University Medical Center, Columbus (Dr Racke), University of California, San Francisco (Drs Zamvil and Weber), and Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany (Drs Weber and Hemmer); Departments of Pathology, Neurology, and Neurosurgery, University of Colorado, Denver (Dr Kleinschmidt-DeMasters); and the Neurology Section, Veterans Affairs North Texas Health Care System, Medical Service, Dallas (Dr Stüve).

OBJECTIVE: To extend our studies on the prolonged and differential effect of natalizumab on T lymphocyte numbers in the cerebrospinal fluid, we investigated the number and phenotypes of leukocytes and the expression of major histocompatibility complex (MHC) classes I and II in cerebral perivascular spaces (CPVS). We hypothesized that natalizumab reduces the number of antigen presenting cells in CPVS. DESIGN: A case-control study in which inflammatory cell numbers in the CPVS of cerebral tissue were assessed by immunohistochemical staining.Subjects A patient with multiple sclerosis (MS) who developed progressive multifocal leukoencephalopathy (PML) during natalizumab therapy.
Controls included location-matched cerebral autopsy material of patients without disease of the central nervous system, patients with MS not treated with natalizumab, and patients with PML not associated with natalizumab therapy.
RESULTS: The absolute number of CPVS in the patient with MS treated with natalizumab was significantly lower than in the control groups owing to extensive destruction of the tissue architecture. The expression of MHC class II molecules and the number of CD209(+) dendritic cells were significantly decreased in the CPVS of the patient with MS treated with natalizumab. No
CD4(+)
T cells were detectable. CONCLUSIONS: Our observations may explain the differential and prolonged effects of natalizumab therapy on leukocyte numbers in the cerebrospinal fluid.Published online October 13, 2008 (doi:10.1001/archneur.65.12.noc80051).
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Tysabri (Antegren, Natalizumab)”